Valuation: Genmab A/S

Market Cap 128B 19.98B 17.11B 15.96B 14.64B 27.52B 1,912B 28.06B 189B 73.81B 958B 75.02B 73.38B 3,172B P/E 2026 *
27.1x
P/E 2027 * 19.1x
Enterprise Value 147B 23.05B 19.73B 18.41B 16.89B 31.74B 2,205B 32.37B 218B 85.14B 1,105B 86.53B 84.65B 3,659B EV / Sales 2026 *
5.08x
EV / Sales 2027 * 4.12x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day+0.51%
1 week+5.62%
Current month+15.20%
1 month+15.57%
3 months+24.33%
6 months+16.83%
Current year+5.62%
1 week 2,047
Extreme 2047
2,187
1 month 1,819.5
Extreme 1819.5
2,187
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

283 0.0004%
12/1/25 Fiscal year

Director

189 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.51%+5.62%+36.02%-14.19% 19.98B
+2.38%+3.43%+82.88%+115.89% 73.96B
+1.08%+22.27%+55.00%+95.75% 64.66B
+0.40%+1.31%-5.46%+469.84% 27.32B
+5.06%+23.38%+3.69%-2.28% 27.86B
+2.74%+12.98%+62.84%+28.14% 25.97B
-1.79%-4.84%+239.54%+414.48% 17.84B
+0.94%+3.36%+18.55%+532.94% 16.24B
+0.45%+5.23%+39.29%+152.32% 13.3B
-0.18%+1.63%+324.34%+207.01% 12.36B
Average +1.19%+5.79%+85.67%+199.99% 29.95B
Weighted average by Cap. +1.56%+7.96%+70.44%+162.33%

Financials

2026 *2027 *
Net sales 29.01B 4.53B 3.88B 3.62B 3.32B 6.25B 434B 6.37B 42.97B 16.75B 217B 17.02B 16.65B 720B 33.71B 5.27B 4.51B 4.21B 3.86B 7.26B 504B 7.4B 49.93B 19.46B 253B 19.78B 19.35B 836B
Net income 4.93B 770M 660M 615M 565M 1.06B 73.7B 1.08B 7.3B 2.85B 36.94B 2.89B 2.83B 122B 7.13B 1.11B 954M 890M 817M 1.53B 107B 1.57B 10.56B 4.12B 53.44B 4.18B 4.09B 177B
Net Debt 19.62B 3.07B 2.63B 2.45B 2.25B 4.22B 293B 4.31B 29.06B 11.33B 147B 11.51B 11.26B 487B 11.13B 1.74B 1.49B 1.39B 1.28B 2.4B 166B 2.44B 16.49B 6.43B 83.42B 6.53B 6.39B 276B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-08-21 DKK 2,151.00 +0.47% 122,551
26-08-20 DKK 2,141.00 -0.51% 144,089
26-08-19 DKK 2,152.00 +2.28% 99,873
26-08-18 DKK 2,104.00 0.00% 108,957
26-08-17 DKK 2,104.00 +3.80% 177,078
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,141.00DKK
Average target price
2,410.46DKK
Spread / Average Target
+12.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock